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To characterize the sugar translocation pathway of Na+/glucose cotransporter type 1 (SGLT1), a chimera was made by substituting the extracellular
loop between transmembrane domain (TM) 12 and TM13 of Xenopus SGLT1-like protein (xSGLT1L) with the homologous region of rabbit SGLT1.
The chimera was expressed in Xenopus oocytes and its transport activity was measured by the two-microelectrode voltage-clampmethod. The substrate
specificity of the chimera was different from those of xSGLT1L and SGLT1. In addition the chimera's apparent Michaelis–Menten constant (Km) for
myo-inositol, 0.06 mM, was about one fourth of that of xSGLT1L, 0.25 mM, while the chimera's apparent Km for D-glucose, 0.8 mM, was about one
eighth of that of xSGLT1L, 6.3 mM. Our results suggest that the extracellular loop between TM12 and TM13 participates in the sugar transport of
SGLT1.
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Na+/glucose cotransporter type 1 (SGLT1) is one of the most
intensively studied membrane transporters (reviews: [1,2]).
SGLT1 is a member of the very large solute carrier family 5
(SLC5); this family has more than 220 members in procaryotes
and eucaryotes (reviews: [3–5]). The proteins in this family
transport various solutes (such as glucose, myo-inositol, amino
acids and iodide) into cells using the Na+ electrochemical
potential gradient across the plasma membrane.
SGLT1 is present mainly in the intestine and kidney and takes
up glucose and galactose into cells. It has been proposed that
SGLT1 has 14 transmembrane domains (TMs) and displays the
extracellular N- and C-termini [3,6]. Regarding the structure–
function relationship, it is thought that the N-terminal half of
SGLT1 participates in Na+ transport [2,7–9] while the C-terminal
half participates in sugar transport [2,10]. Ala-166 and Asp-454
are suggested to link the Na+ and sugar translocation pathways
[11,12]. However, except for a few residues responsible for sugar⁎ Corresponding author. Tel.: +81 859 38 6252; fax: +81 859 38 6250.
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doi:10.1016/j.bbamem.2006.05.002binding and/or translocation [2,13], the detailed structure of the
sugar binding site of SGLT1 is yet unknown.
We have cloned and characterized an SGLT1 homologue from
the Xenopus laevis intestine and named it Xenopus SGLT1-like
protein (xSGLT1L) [14]. xSGLT1L transportsmyo-inositol better
than D-glucose, and transports D-galactose and α-methyl-D-
glucoside (αMG) (a specific substrate for SGLT) poorly, while
SGLT1 transports D-glucose, D-galactose and αMG well, and
transports myo-inositol poorly [15]. Therefore, the substrate
specificity of xSGLT1L is similar to that of Na+/myo-inositol
cotransporter (SMIT) [15], another member of the SLC5 family,
rather than that of SGLT1. Recently it was shown that xSGLT1L
is a member of the ST1 subfamily in SLC5 [16]. According to its
substrate specificity, ST1 has been renamed SMIT2 and the
original or previously cloned SMIT has been renamed SMIT1
[17]. On the other hand, ST1 is called SGLT6 in the latest review
[5]. Based on a comparison of the amino acid sequences among
xSGLT1L, SGLT1 and SMIT1, we speculated that the extracel-
lular loop between TM12 and TM13 must contain at least one
crucial residue for sugar binding and/or translocation.
Making chimeras from SGLT1 and other members of the
SLC5 family is one of the useful strategies for identifying residues
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cDNAhas two useful restriction enzyme sites in TM12 and TM13
for making chimeras (see Fig. 1). In the present study, we made a
chimera inwhich the extracellular loop between TM12 and TM13
of xSGLT1L was replaced by the homologous region of rabbit
SGLT1, and examined its transport properties.
2. Materials and methods
2.1. Chimera generation
A chimeric protein was made by substituting the extracellular loop between
TM12 and TM13 of xSGLT1Lwith the homologous region of rabbit SGLT1 (Fig. 1).
The rabbit SGLT1 cDNAwas generously provided by Dr. E. M. Wright [18]. Using
the rabbit SGLT1 cDNA as template, a PCR fragment was obtained using the
following primers: sense, 5′-GATTTTTCGAATGGTTCTCGATTTTATCTATG-
GAACC-3′; and anti-sense, 5′-AAGAAGCTTACAGCCACAACGACGAGGA-
GAGTAAGGAGACCGAGGA-TCATGGACAAGTACAAGT-3′. The restriction
site ofCsp 45I is underlined and the site ofHindIII is italicized. The positions of these
two restriction sites in the xSGLT1L cDNA are shown in Fig. 1. There are no sites for
these two enzymes in the corresponding region of the rabbit SGLT1 cDNA. The
primers were designed so that the PCR product encoded a polypeptide in which the
amino acid sequence fromGly-507 toGly-523 of rabbit SGLT1 (under the dotted line
in Fig. 1) was conserved but the remainder of the sequence was replaced by that of
xSGLT1L.After digestion byCsp 45I andHindIII, the PCRproduct was inserted into
a plasmid containing the full-length xSGLT1L cDNA [14] that had been digestedwith
the same enzymes. The nucleotide sequence of the chimeric cDNAwas confirmed by
sequencing.
cRNAwas synthesized from the linearized plasmid containing the chimeric or
xSGLT1L cDNA using an mCAP mRNA capping kit (Stratagene). The transcript
was dissolved in diethyl pyrocarbonate (DEPC)-treated water at 0.5 μg/μl.
2.2. Expression and electrophysiology
A female frog (Xenopus laevis) was anesthetized in ice-cold water containing
0.1% ethyl m-aminobenzoate methanesulfonate. A piece of the ovary was
surgically excised and incubated at 20 °C for 1 h in the presence of 1 mg/ml
collagenase (type I, Sigma-Aldrich Co., St. Louis, MO) in Barth's solution. The
composition of Barth's solution was 88 mMNaCl, 1 mMKCl, 2.4 mMNaHCO3,
0.82 mMMgSO4, 0.33 mM Ca(NO3)2, 0.91 mM CaCl2, 10 mM HEPES–NaOH,Fig. 1. Amino acid sequence alignment of Xenopus SGLT1-like protein (xSGLT1L), d
sequence is shown. Amino acids conserved in two or three of the proteins are shaded
labeled ‘chimera’ indicates the region used to make the chimera. Arrows indicate the p
asterisk denotes Gln-457 in rabbit SGLT1. Sequence alignment was performed usinpH 7.4, and 0.01mg/ml penicillin and streptomycin. Then the oocytes in stages V–
VI were defolliculated manually using tweezers. The defolliculated oocytes were
incubated overnight at 20 °C in Barth's solution and viable oocytes were injected
with 40–46 nl of cRNA solution with a glass micropipette using NANOJECT II
(Drummond Scientific Co., Broomall, PA). The oocytes were incubated in Barth's
solution at 20 °C, with daily medium changes until use.
Membrane currents from oocytes were measured by the two-microelectrode
voltage-clamp method [14]. Briefly, the oocytes were superfused with a solution
containing 88 mMNaCl, 2 mMKCl, 1.8 mMCaCl2, and 10 mMHEPES–NaOH,
pH 7.4. Oocytes were voltage clamped at −60 mV between 3 and 20 days after the
injection. Measurements were done at room temperature (20–25 °C). Data acqui-
sition and membrane voltage control were performed using pCLAMP 6 (Axon
Instruments Inc., Union City, CA).Membrane currents were filtered at 100Hzwith
an RC filter and sampled at 250Hz, and records were further filtered at 10Hz using
pCLAMP 6.
2.3. Kinetic parameters
The chimera's apparent Michaelis–Menten constants (Kms) for myo-inositol and
D-glucose were calculated using OriginPro 7.5J (OriginLab Co., Northampton, MA).
The chimera's apparent inhibition constant (Ki) for phlorizin, which is a
competitive inhibitor of xSGLT1L [14], as well as SGLTand SMIT, was calculated
as follows (see Fig. 5). From one chimera-expressing oocyte currents induced by 1
and 20 mM myo-inositol in the presence of 0.1 mM phlorizin or 20 mM myo-
inositol in the absence of phlorizin were recorded twice under each condition. The
currents were plotted on an Eadie–Scatchard plot. In this plot the currents induced
by 20 mM myo-inositol alone were plotted on the x-axis for two reasons: (1) this
chimera exhibits the maximum current response (Imax) to 20 mMmyo-inositol (see
Discussion) and (2) Imax is the same whether phlorizin is present or not because
inhibition by phlorizin is competitive. Then, the linewas drawn by the least-squares
method using OriginPro 7.5J. The line can be described by the equation
Im=½MI ¼ −Im=Km Vþ Imax=Km V ð1Þ
where Im is the current elicited by the chimera, [MI] is the concentration of myo-
inositol and Km' is the apparent Michaelis–Menten constant in the presence of
inhibitor. Finally the apparent Ki was calculated using the following equation [19]:
Km V¼ Kmð1þ ½I=KiÞ ð2Þ
where Km is the apparent Michaelis–Menten constant in the absence of inhibitor
and [I] is the concentration of inhibitor.og SMIT1 (dSMIT-1) and rabbit SGLT1 (rbSGLT-1). Part of the complete coding
black. Bars labeled with Roman numerals indicate putative TMs. The dotted line
ositions of two restriction sites, Csp 45I andHindIII, in the xSGLT1L cDNA. The
g GENETYX-SV/RC version 6 (Software Development, Tokyo, Japan).
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3.1. Sequence comparison of xSGLT1L, SMIT1 and SGLT1
Fig. 1 shows a part of the sequence alignment of xSGLT1L [14],
dog SMIT1 [20] and rabbit SGLT1 [18]. Putative TMs are assignedFig. 2. Substrate specificity of the chimera and xSGLT1L. Membrane current
recordings are shown. (A) Non-injected (control), (B) chimeric cRNA-injected
and (C) xSGLT1L cRNA-injected oocyte. Inward currents are shown in the
downward direction. Oocytes were clamped at −60 mV and superfused with
substrates: MI, myo-inositol; Glc, D-glucose; αMG, α-methyl-D-glucoside; Gal,
D-galactose. Substrate concentrations were all 20 mM. Superfusion periods are
indicated by shaded boxes above the traces. Oocytes in A–Cwere from the same
batch; B and C were recorded 12 days after the injection and A was recorded
14 days after the defolliculation. (D) relative amplitude of the substrate-induced
current in chimera- or xSGLT1L-expressing oocytes. Open boxes, xSGLT1L,
n=6; closed boxes, chimera, n=14: error bars denote SD.
Fig. 3. myo-inositol dependency of the chimera. (A) A current record from a
chimera-expressing oocyte is shown. The downward direction means the inward
current. Concentrations of myo-inositol are indicated above the current trace.
This oocyte was voltage clamped at −60 mV 12 days after the injection. (B)
Current responses in A were plotted against myo-inositol concentration. The
solid line was curve fitted by Michaelis–Menten-type kinetics with Imax=20.0
nA and the apparent Km=0.05 mM.according to the 14 membrane-spanning model of SGLT1 [3,6]. It
is thought that the sugar permeation pathway of SGLT1 utilizes
TM10–13 because a truncated SGLT1 which was made from the
last 5 TMs (TM10–14) worked as a glucose uniporter [10] and
some members of the SLC5 family lack the 14th TM [3,4]. The
overall amino acid sequence of xSGLT1L shares 53% identity with
that of rabbit SGLT1 and 46% identity with that of dog SMIT1.
Therefore, the extracellular loop between TM12 and TM13 is
somewhat anomalous, because the loop of xSGLT1L is very
similar to that of dog SMIT1 but is not so similar to that of rabbit
SGLT1. We hypothesized that important amino acids in sugar
binding and/or translocation are located in this loop, and made a
chimeric protein inwhich the extracellular loop betweenTM12 and
TM13 (including the last amino acid of TM12) of xSGLT1L was
replaced by the homologous region of rabbit SGLT1.
3.2. Expression of the chimera
In control oocytes, 20 mM D-glucose and αMG induced
small inward currents (Fig. 2A) that were probably due to the
Fig. 4. D-glucose dependency of the chimera. (A) A current record from a
chimera-expressing oocyte is shown. Concentrations of D-glucose are indicated
above the current trace. This oocyte was voltage clamped at −60 mV 15 days
after the injection. (B) Current responses in A were plotted against D-glucose
concentration. The solid line was curve fitted by Michaelis–Menten-type
kinetics with Imax=14.0 nA and the apparent Km=0.8 mM.
Fig. 5. Inhibition of the chimera by phlorizin. Currents induced by 1 and 20 mM
myo-inositol in the presence of 0.1 mM phlorizin or 20 mM myo-inositol in the
absence of phlorizin from one chimera-expressing oocyte were plotted on an
Eadie–Scatchard plot. The line was drawn by the least-squares method. In this
example, the apparent Ki for phlorizin was 3.1 μM. This oocyte was voltage
clamped at −60 mV 19 days after the injection.
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perience the endogenous current was not always observed and
never exceeded 2 nA.
Fig. 2B shows the transport current elicited by the chimera
expressed in Xenopus oocytes. Expression of the chimera was
much weaker than that of xSGLT1L (Fig. 2C). In the batch
of oocytes (all obtained at one time from one frog) shown in Fig.
2A–C, the 20mMmyo-inositol-induced current of the chimerawas
6.5±1.7 nA (mean±SD, n=6) while that of xSGLT1Lwas 71±48
nA (n=4), when the membrane potential was held at −60 mV.
Using four batches of oocytes, we compared the expression
between the chimera and xSGLT1L. The relative amplitude of the
20 mM myo-inositol-induced current of the chimera was 17±6%
(n=4) when normalized by that of xSGLT1L in each batch. The
transport current of the chimera never exceeded 30 nA.
The substrate specificity of the chimera is compared with that
of xSGLT1L in Fig. 2D. The peak amplitude of substrate-induced
current in each chimera- or xSGLT1L-expressing oocyte was
normalized relative to the myo-inositol-induced current in each
oocyte. Substrate concentrations were all 20mM. The data for the
chimera were obtained from two batches: data from one batch areshown in Fig. 2A–C and in the other batch the 20 mM myo-
inositol-induced current was 11.0±3.8 nA (mean±SD, n=8).
Data on xSGLT1L in Fig. 2D are from our previous report [14].
The substrate specificity of the chimera was different from those
of xSGLT1L and SGLT1. The order of substrate specificity of
SGLT1wasαMG≈D-glucose≈D-galactose≫myo-inositol [15].
It should be noted that the chimera's relative responses elicited
by D-glucose and αMGmight have been overestimated due to the
endogenous SGLTactivity inXenopus oocytes. Also the extent of
overestimation for αMG would be larger than that for D-glucose
because the chimera's current induced by D-glucose was about
two times larger than that induced by αMG whereas the
endogenous currents induced by the two sugars are almost the
same. The overestimation was at most 20% for αMG (data not
shown).
Fig. 3 shows the myo-inositol dependence of the chimera
recorded from one oocyte. The current amplitude obeyed
Michaelis–Menten-type kineticswithmyo-inositol concentration,
and in this example the apparent Km was 0.05 mM (Fig. 3B, the
solid line). From six oocytes in two batches the chimera's
apparent Km for myo-inositol was 0.06±0.02 mM and Imax was
11.0±6.4 nA at the membrane potential of −60 mV. The
chimera's apparent Km for myo-inositol was about one fourth of
that of xSGLT1L, 0.25±0.07 mM (n=7) [14].
Fig. 4 shows the D-glucose dependence of the chimera recor-
ded from one oocyte. The current amplitude obeyed Michaelis–
Menten-type kinetics with D-glucose concentration, and in this
example, the apparent Km was 0.8 mM (Fig. 4B, the solid line).
From five oocytes in two batches the chimera's apparentKm for D-
glucose was 0.8±0.2 mM and Imax was 7.7±4.3 nA at the mem-
brane potential of −60 mV. Because the control or endogenous
current elicited by 20 mM D-glucose was only 0.3±0.3 nA (n=6)
in the two batches, we ignored it in calculating kinetic parameters.
The chimera's apparentKm for D-glucose was about one eighth of
that of xSGLT1L, 6.3±1.2 mM (n=5)[14].
Fig. 6. D-chiro-inositol (DC) response of xSGLT1L. Membrane current recordings are shown. (A) xSGLT1L cRNA-injected and (B) non-injected (control) oocyte.
Concentrations of DC andMI were 1 mM. The membrane potential was held at −60 mV. Oocytes in A and B were from the same batch; Awas recorded 6 days after the
injection and B was recorded 7 days after the defolliculation.
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competitive inhibitor of xSGLT1L, SGLT and SMIT, was calcu-
lated as shown in Fig. 5 (see Materials and methods). From four
oocytes in two batches the apparent Ki for phlorizin was 3.6±
1.0 μM and Imax was 7.3±3.5 nA at the membrane potential of
−60 mV. On the other hand, the apparent Ki of xSGLT1L for
phlorizin was 7.3±2.3 μM (n=7) [14].We are unable to discern a
significant difference between the Ki values for phlorizin differ
between xSGLT1L and the chimera.
3.3. D-chiro-inositol response of xSGLT1L
xSGLT1L is most closely related to rabbit SMIT2 [24]: they
are 67% identical in amino acid sequence. However, whether
xSGLT1L and SMIT2 are orthologous or not has been ambi-
guous [17]. SMIT2 transports D-chiro-inositol as well as myo-
inositol [17], so we examined the D-chiro-inositol response in
xSGLT1L-expressing oocytes. When superfused with 1 mM D-
chiro-inositol, xSGLT1L induced a current comparable to that
induced by 1 mM myo-inositol (Fig. 6A). The same results were
obtained in eight additional xSGLT1L-expressing oocytes from
three batches. Our results suggest that xSGLT1L and SMIT2 are
orthologous.
4. Discussion
The structure–function relationship of SGLT1 is largely
unknown because of the lack of crystallographic data. However,
a general outline has emerged: the Na+ translocation pathway
consists of the N-terminal half [2,7–9] and the sugar translocation
pathway consists of the residual C-terminal half [2,10]. Fur-
thermore, it has been reported that in SGLT1, Gln-457 is im-
portant for sugar binding and translocation [13] and Thr-460
participates in discrimination between D-glucose and D-galactose
[13,17]. To search for amino acids other than Gln-457 and Thr-460 that are important for sugar transport, we compared the amino
acid sequence from TM10 to TM13 among xSGLT1L, dog
SMIT1 and rabbit SGLT1 (Fig. 1). We speculated that the extra-
cellular loop between TM12 and TM13 must be important for
sugar transport because in this loop the amino acid sequence of
xSGLT1L is similar to that of dog SMIT1 but not to that of rabbit
SGLT1, while with respect to substrate specificity, xSGLT1L is
similar to SMIT1 rather than SGLT1 [14,15].
4.1. Weak expression of the chimera
We made a chimeric protein in which the extracellular loop
between TM12 and TM 13 of xSGLT1L (including the last amino
acid of TM12) was replaced by the homologous region of rabbit
SGLT1 (Fig. 1), and expressed it in Xenopus oocytes. Before
performing the experiments, we expected that the chimera would
be expressed well because both xSGLT1L and SGLT1 are
expressed well in Xenopus oocytes [1,13–15]. However, the
current elicited by the chimera was about one sixth of that elicited
by xSGLT1L and never exceeded 30 nA (see Results).
We think that the weak expression of the chimera was probably
due to a defect in targeting of the protein to the plasmamembrane. It
has been reported that 22 out of the 23 missense mutations
identified in glucose–galactose malabsorption (GGM) did not
reach the plasma membrane when expressed in Xenopus oocytes
[25]. In our chimera the substitutions observed in GGM did not
occur, but some of the substituted amino acids in our chimeramight
have affected the targeting. In addition, it was shown that the
surface density of the chimera named C1, in which the N-terminal
69 amino acids of SGLT1were replaced by the first 50 amino acids
of SMIT1, was about one seventh that of SGLT1 in the Xenopus
oocyte plasma membrane [26]. This means that the substitution of
the homologous region even between SGLT1 and SMIT1 might
decrease the stability of C1 and/or induce incorrect targeting of C1.
The same kind of disturbance might have affected our chimera.
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Before considering the substrate specificity of the
chimera, we note that whether xSGLT1L and SMIT2 are
orthologous or not has been ambiguous [17]. The most
obvious difference between the two proteins is their tissue
distribution: for example, xSGLT1L is expressed in the
intestine [14] but SMIT2 is not [24,27]. In the present study
we showed that xSGLT1L transported D-chiro-inositol as
well as myo-inositol (Fig. 6). SMIT2 also transports both
substances to the same extent [17], and therefore we think
the two proteins are orthologous. As pointed out by Coady
et al. [17], in the course of evolution the two proteins have
acquired somewhat different roles between amphibians and
mammals.
The substrate specificity of the chimera was different from
those of xSGLT1L (Fig. 2) and SGLT1 [15]. Two obvious
features of the substrate specificity of the chimera are as
follows: (1) the currents induced by 20 mM myo-inositol and D-
glucose were almost the same in amplitude and (2) the relative
responses elicited by 20 mM αMG and D-galactose were larger
than those of xSGLT1L.
We think that the chimera's apparent affinities for the four
substrates we tested increased simultaneously. Also the first
feature of the chimera's substrate specificity can be explained
by the fact that the chimera's apparent Kms for myo-inositol and
D-glucose are 0.06 and 0.8 mM while those of xSGLT1L are
0.25 mM and 6.3 mM [14]. In the Michaelis–Menten-type
kinetics (where myo-inositol and D-glucose show the same
Imax), the 20 mM D-glucose-induced current increases from 76
to 96% of Imax when the apparent Km decreases from 6.3 to
0.8 mM, whereas the 20 mM myo-inositol-induced current
increases from 99 to 100% of Imax when the apparent Km
decreases from 0.25 to 0.06 mM [19]. Although 76% of Imax,
the theoretical xSGLT1L response induced by 20 mM D-
glucose, is somewhat larger than the measured value, 54±6%
(Fig. 2D), our explanation would still be essentially correct.
It has been thought that the amino acid at position 460 is
important in the discrimination between D-glucose and D-
galactose [13,17]. SGLT1 has Thr-460 and transports D-glucose
and D-galactose equally [15] whereas SGLT2 and SMIT2
(including xSGLT1L) have Ser at that position (Ser-460) and
prefer D-glucose to D-galactose as a substrate [14,17,30,33].The
fact that the chimera contained Ser-460 and had a higher affinityFig. 7. Sequence comparison of the region used to make the chimera. SMIT2 includes
conserved in four proteins are shaded black, and those conserved in two proteins are s
511 and Glu-513, respectively, in SGLT1. Orthologues included in the figure are as f
bovine SMIT1 [40]; human, mouse, rat, rabbit and pig SGLT1 [3]; human, mouse,for D-glucose as compared to D-galactose supports the notion that
Ser-460 plays a critical role in the substrate recognition of SGLT.
We compare the region used tomake the chimera among SMIT2
(including xSGLT1L), SMIT1, SGLT1 and SGLT2 in Fig. 7. In this
figure, amino acids conserved in three or five orthologues are
shown. This figure shows that the sequences are fairly different
between SMIT and SGLT, and seven amino acids are different
between SMIT2 and SGLT1 (and conserved in each orthologue):
(numbers in SGLT1) Gly-507, Gly-509, Glu-513, Ser-515, Cys-
517, Ile-521 andCys-522. Of these seven amino acidsGlu-513 (the
arrow in Fig. 7) is most interesting. Human SGLT2 has Gln [28] as
well as in SMIT1 and SMIT2, whereas mouse, rat, rabbit and
bovine SMIT2 have Arg [29–32] at that position. The apparentKm
for αMG is 3.0 mM in rat SGLT2 (Arg-513, +1 charge) [30], and
this value is about two times larger than that of humanSGLT2 (Gln-
513, 0), 1.6 mM [33]. The affinity is further increased in SGLT1
(Glu-513, −1); the apparent Km for αMG is 0.05–0.5 mM in rat,
human and rabbit SGLT1 [34]. Therefore, Glu-513 or its −1 charge
may be important for the high affinity of SGLT1 for D-glucose and
αMG.We also speculate that the increase in the apparent affinity for
D-glucose of the chimera was at least partly due to the Gln-513-Glu
substitution.
Lately it has been reported that Cys-255 and Cys-511 (the
arrowhead in Fig. 7) make a disulfide bond in SGLT1 [41]. By
breaking this disulfide bond the Q–V curve of the presteady-state
current was shifted by +25mVand the apparentKm for αMGwas
increased by 60%. Although the authors of that study did not
explain why the apparentKm was increased, we think that a small
change in the loop structure induced by breaking the disulfide
bond might be the cause.
Our results clearly show that the extracellular loop between
TM12 and TM13 participates in the sugar transport of SGLT1.
Although the loop may not be a part of the sugar binding site,
but it may work as a kind of a selectivity filter at the entrance of
the sugar translocation pathway.
4.3. Phlorizin binding
The chimera's apparent Ki for phlorizin was not different
from that of xSGLT1L (see Results). This is probably because
the apparent Ki is mainly determined by the interaction between
the protein and the aglucone of phlorizin. However, which
region of SGLT1 interacts with the aglucone of phlorizin cannot
be inferred from our results on the chimera.xSGLT1L. Hyphens indicate amino acids that differ in orthologues. Amino acids
haded dark or light gray. The arrowhead and arrow indicate the positions of Cys-
ollows: xSGLT1L [14] and human [27] and rabbit SMIT2 [24]; human, dog and
rat, rabbit and bovine SGLT2 [32].
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to 610 (aa 604–610) of SGLT1 bind to the aglucone of phlorizin
[35,36]. The authors of those studies claimed that the region aa
604–610 is extracellular [37]. However, according to the 14
membrane-spanning model of the SLC5 family, this region is
intracellular [2–4,6,38]. Lately it was also suggested that the
large loop between TM13 and TM14, namely aa 549–639, of
SGLT1 would start and finish at an intracellular localization and
could form some kind of re-entrant loop, allowing accessibility
from the extracellular solution [39]. This re-entrant loop model
seems to be compatible with most of the results concerning the
position of the loop; however, the authors of this model also
suggest that the loop does not appear to play a major part in the
binding of phlorizin [39].
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